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Introduction
Neonatal Onset Multisystem Inflammatory Disorder
(NOMID) is the most severe of the Cryopyrin-Associated
Periodic Syndromes (CAPS) spectrum [1]. Given the per-
sistent nature of CAPS, symptoms may be confused with
autoimmune diseases. However, unlike autoimmune dis-
eases, autoinflammatory disorders are not associated with
high-titer autoantibodies or antigen-specific T cells. Here
we describe a patient with severe and early onset features
of NOMID confirmed by NLRP3 mutation, hepatitis,
neonatal antibodies and a limited response to high dose
anakinra.
Case report
N.D. is a 2.5 yo male with congenital hearing loss who
initially presented at 2 months of age with direct hyper-
bilirubinemia and transaminitis. Liver biopsy showed
giant cell hepatitis. He had a positive ANA (with strong
cytoplasmic staining), anti-smooth muscle antibody, and
mildly positive double-stranded DNA antibody although
his mother had no autoimmune antibodies. At 3 months
of age, he developed persistent fevers and an urticarial-
like rash and at 1 year he developed hip arthritis followed
by knee swelling. His physical exam was notable for poor
growth, macrocephaly, and irritability. He had general-
ized lymphadenopathy, pronounced hepatosplenomegaly
and arthralgia with effusion of the left knee. Laboratory
evaluations demonstrated persistently elevated CRP up to
200 mg/L, ESR 76 mm/hr, and ferritin 114 ng/mL. Urine
showed no proteinuria or mevalonic acid. MRI of the
brain demonstrated severe volume loss and Xray of distal
femur showed physeal irregularity. Skin biopsy showed
neutrophilic urticaria particularly surrounding eccrine
glands. Sequencing of NLRP3 revealed a c.926T>A muta-
tion (Phe209Leu) which was described in a NOMID
patient [1]. Despite treatment with anakinra, his clinical
course has been complicated by uveitis, anemia, rib frac-
tures with rachitic changes suggestive of vitamin D-
deficiency rickets, chronic diarrhea and fat malabsorption,
abnormal hearing, left knee reactive synovitis, seizures and
significant developmental delay in speech, and both fine
and gross motor skills. While he demonstrated an initial
modest improvement on 4mg/kg anakinra [2,3] including
decreased rash, improved mobility and development, and
slow but steady weight gain, he continues to have inter-
mittent rashes, irritability and enlarging head circumfer-
ence despite dose escalation to 11mg/kg. In addition,
he has a severe, persistent unilateral knee synovitis with
minimal response to therapy.
Discussion
This complex patient with evidence for persistent
inflammation emphasizes the variable clinical presentation
of the CAPS spectrum. The severity of this case also illus-
trates that NLRP3-related inflammation may begin
in utero and suggests that in some cases, autoinflamma-
tion and autoimmunity may not be mutually exclusive.
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